Non-viral delivery of ribozymes for cancer gene therapy

被引:8
作者
Kashani-Sabet, M
机构
[1] UCSF, Ctr Comprehens Canc, Melanoma Ctr, Auerback Melanoma Res Lab,Cutaneous Oncol Program, San Francisco, CA 94115 USA
[2] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA
关键词
metastasis; molecular therapeutics; RNA catalysis; targeted therapy;
D O I
10.1517/14712598.4.11.1749
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ribozymes are RNA molecules with the capacity to effect sequence-specific cleavage of other transcripts. Since their initial discovery, there has been considerable interest in the development of ribozymes and other RNA therapeutics for gene therapy, particularly in the realm of cancer. However, as with other gene therapy applications, the delivery of ribozyme-based therapeutics to the target tissues of interest has represented a significant obstacle to the maturation of this technology to the clinical arena. This review will discuss the progress made so far in the use of non-viral methods for the systemic delivery of ribozymes for cancer gene therapy.
引用
收藏
页码:1749 / 1755
页数:7
相关论文
共 53 条
[1]   Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression [J].
Aigner, A ;
Fischer, D ;
Merdan, T ;
Brus, C ;
Kissel, T ;
Czubayko, F .
GENE THERAPY, 2002, 9 (24) :1700-1707
[2]  
Akiyama M, 2003, CANCER RES, V63, P18
[3]   Ribozymes in the age of molecular therapeutics [J].
Bagheri, S ;
Kashani-Sabet, M .
CURRENT MOLECULAR MEDICINE, 2004, 4 (05) :489-506
[4]   Identification of a functional NF-κB site in the platelet endothelial cell adhesion molecule-1 promoter [J].
Botella, LM ;
Puig-Kröger, A ;
Almendro, N ;
Sánchez-Elsner, T ;
Muñoz, E ;
Corbí, A ;
Bernabéu, C .
JOURNAL OF IMMUNOLOGY, 2000, 164 (03) :1372-1378
[5]   Dissemination and growth of cancer cells in metastatic sites [J].
Chambers, AF ;
Groom, AC ;
MacDonald, IC .
NATURE REVIEWS CANCER, 2002, 2 (08) :563-572
[6]   Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin [J].
Czubayko, F ;
Schulte, AM ;
Berchem, GJ ;
Wellstein, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14753-14758
[7]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[8]  
GELMON KA, 2003, P 94 ANN M AM ASS CA
[9]  
Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241
[10]   The IKK/NF-κB activation pathway -: a target for prevention and treatment of cancer [J].
Greten, FR ;
Karin, M .
CANCER LETTERS, 2004, 206 (02) :193-199